PUMA BIOTECHNOLOGY
Puma Biotechnology, Inc., is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. The Company is initially focused on the development of PB-272 (oral neratinib), a potent irreversible tyrosine kinase inhibitor, for the treatment of patients with HER2 positive metastatic breast cancer.
PUMA BIOTECHNOLOGY
Industry:
Biotechnology Medical Therapeutics
Founded:
2010-01-01
Address:
Los Angeles, California, United States
Country:
United States
Website Url:
http://www.pumabiotechnology.com
Total Employee:
251+
Status:
Active
Contact:
310-443-4150
Total Funding:
809.3 M USD
Technology used in webpage:
SPF SSL By Default Google Font API Google Analytics Google Tag Manager Content Delivery Network Google Universal Analytics Font Awesome Domain Not Resolving Global Site Tag
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Current Advisors List
Board_member
2019-11-01
Board_member
Current Employees Featured
Gordon Esplin VP Finance @ Puma Biotechnology
VP Finance
2020-10-01
Charles Eyler Senior Vice President, Finance and Administration and Treasurer @ Puma Biotechnology
Senior Vice President, Finance and Administration and Treasurer
Alan H. Auerbach Chief Executive Officer & President @ Puma Biotechnology
Chief Executive Officer & President
2010-01-01
Founder
Stock Details
Investors List
Athyrium Capital Management LP
Athyrium Capital Management LP investment in Post-IPO Equity - Puma Biotechnology
Alan H. Auerbach
Alan H. Auerbach investment in Post-IPO Equity - Puma Biotechnology
Armentum Partners
Armentum Partners investment in Post-IPO Debt - Puma Biotechnology
Athyrium Capital Management LP
Athyrium Capital Management LP investment in Post-IPO Debt - Puma Biotechnology
Silicon Valley Bank
Silicon Valley Bank investment in Post-IPO Equity - Puma Biotechnology
Oxford Finance LLC
Oxford Finance LLC investment in Post-IPO Equity - Puma Biotechnology
OrbiMed
OrbiMed investment in Post-IPO Equity - Puma Biotechnology
Sahsen Ventures
Sahsen Ventures investment in Post-IPO Equity - Puma Biotechnology
H&Q Healthcare Investors
H&Q Healthcare Investors investment in Post-IPO Equity - Puma Biotechnology
T. Rowe Price
T. Rowe Price investment in Post-IPO Equity - Puma Biotechnology
Official Site Inspections
http://www.pumabiotechnology.com Semrush global rank: 4.23 M Semrush visits lastest month: 2.78 K
- Host name: 33.187.62.50.host.secureserver.net
- IP address: 50.62.187.33
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Puma Biotechnology"
Puma Biotechnology - Wikipedia
Puma was founded in September 2010 by Alan Auerbach to identify and in-license compounds that were already in clinical development. This was the same business plan Auerbach had followed at Cougar Biotechnology, which he founded in 2003, and through which he in-licensed abiraterone acetate from BTG plc. Cougar further developed abiraterone before the company was sold to Johnson & Johnson in 2009. Auerbach brought many Cougar employees with him after fo…See details»
Puma Biotechnology - Crunchbase Company Profile
Contact Email info@pumabiotechnology.com Phone Number 310-443-4150 Puma Biotechnology, Inc., is a development stage biopharmaceutical …See details»
Puma Biotechnology, Inc. | LinkedIn
Puma Biotechnology, Inc. Biotechnology Research Los Angeles, CA 10,077 followers At Puma Biotechnology, our focus is on bringing innovative therapies to patients to enhance cancer care.See details»
2025 Latest News | Feb. 27, 2025 - Puma Biotechnology …
Further information about Puma Biotechnology may be found at https://www.pumabiotechnology.com. Contact: Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500 …See details»
Puma Biotechnology, Inc. Company Profile | Los Angeles, CA ...
Find company research, competitor information, contact details & financial data for Puma Biotechnology, Inc. of Los Angeles, CA. Get the latest business insights from Dun & Bradstreet.See details»
Puma Biotechnology, Inc. - Resources - Investor FAQs
Ir@pumabiotechnology.com. David Schull Russo Partners, LLC. david.schull@russopartnersllc.com. Investor Email Alerts. To opt-in for investor email alerts, …See details»
Working At Puma Biotechnology: Company Overview and Culture
Pumabiotechnology.com. Organization Type. Public. Social Media. Puma Biotechnology, Inc., is a development stage biopharmaceutical company that acquires and develops innovative …See details»
Puma Biotechnology - Overview, News & Similar companies
View Puma Biotechnology (www.pumabiotechnology.com) location in California, United States , revenue, industry and description. Find related and similar companies as well as employees …See details»
Puma Biotechnology, Inc. - Company Profile & Staff Directory
About Puma Biotechnology, Inc. At Puma Biotechnology, our focus is on bringing innovative therapies to patients to enhance cancer care. We are thankful to be part of the HER2+ breast …See details»
Puma Biotechnology
1Dick F Cancer Discovery Feb 2019, Gong X Cancer Discov 2019 13 Synthetic Lethality of AURKA and Rb1 • Loss of function of Rb1 is a common event in cancer and can emerge as a …See details»
Puma Biotechnology - Craft
Oct 29, 2024 Puma Biotechnology has 4 employees at their 1 location and $230.47 m in annual revenue in FY 2024. See insights on Puma Biotechnology including office locations, …See details»
Puma Biotechnology Announces $10 Million Private Placement
Mar 10, 2022 Further information about Puma Biotechnology may be found at https://www.pumabiotechnology.com. Alan H. Auerbach or Mariann Ohanesian, Puma …See details»
Puma Biotechnology, Inc. - Investor Relations
Feb 27, 2025 ir@pumabiotechnology.com. David Schull Russo Partners, LLC. david.schull@russopartnersllc.com. Investor Email Alerts. To opt-in for investor email alerts, …See details»
Puma Biotechnology Releases Updated Corporate Presentation
Jan 10, 2022 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, provided an update to the corporate presentation that its Chief Executive Officer and …See details»
Puma Biotechnology
This presentation contains forward-looking statements, including statements regarding commercialization of NERLYNX® and the potential indicationsSee details»
Clinical Trials - pumabiotechnology.com
Jan 15, 2025 Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in …See details»
PUMA REDEFINES THE GAME: UNVEILING A BOLD STRATEGY AND …
Mar 20, 2025 The 2025 campaign kicks off with the release of the ‘Go Wild’ hero film, a tribute to runners unlocking the runner’s high – a rush of happy chemicals released during physical …See details»
Puma Biotechnology Releases Updated Corporate Presentation
Jan 9, 2023 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, provided an update to the corporate presentation that its Chief Executive Officer and …See details»
News | 2024 - pumabiotechnology.com
Nov 20, 2024 Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in …See details»
Puma Biotechnology, Inc. - Puma Biotechnology Reports Fourth …
Feb 27, 2025 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2024. Unless …See details»